Cargando…
Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053916/ https://www.ncbi.nlm.nih.gov/pubmed/36983910 http://dx.doi.org/10.3390/life13030755 |
_version_ | 1785015527504084992 |
---|---|
author | Obradović, Dušanka Popović, Milica Banjac, Maja Bulajić, Jelena Đurović, Vladimir Urošević, Ivana Milovančev, Aleksandra |
author_facet | Obradović, Dušanka Popović, Milica Banjac, Maja Bulajić, Jelena Đurović, Vladimir Urošević, Ivana Milovančev, Aleksandra |
author_sort | Obradović, Dušanka |
collection | PubMed |
description | Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective study included hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive ventilation receiving standard of care (SOC) or SOC in addition to baricitinib. Data on patients’ characteristics, pro-inflammatory markers, D dimer, and National Early Warning Score 2 (NEWS2) values were collected and compared between groups. The primary endpoint was 28-day all-cause in-hospital mortality and the secondary outcome was transfer to the ICU. Results. The study included 125 patients. The primary outcome was observed in 44.8% of them: 27% in the baricitinib group vs. 62% in the SOC group, p < 0.001. Transfer to the ICU ward was significantly lower in the baricitinib group: 29% vs. 81%, p < 0.001. A significant improvement was observed when the baricitinib group was compared to SOC in procalcitonin, CRP, D-dimer, neutrophil-to-lymphocyte ratio values, and NEWS2. Conclusion. Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy. |
format | Online Article Text |
id | pubmed-10053916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100539162023-03-30 Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study Obradović, Dušanka Popović, Milica Banjac, Maja Bulajić, Jelena Đurović, Vladimir Urošević, Ivana Milovančev, Aleksandra Life (Basel) Article Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective study included hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive ventilation receiving standard of care (SOC) or SOC in addition to baricitinib. Data on patients’ characteristics, pro-inflammatory markers, D dimer, and National Early Warning Score 2 (NEWS2) values were collected and compared between groups. The primary endpoint was 28-day all-cause in-hospital mortality and the secondary outcome was transfer to the ICU. Results. The study included 125 patients. The primary outcome was observed in 44.8% of them: 27% in the baricitinib group vs. 62% in the SOC group, p < 0.001. Transfer to the ICU ward was significantly lower in the baricitinib group: 29% vs. 81%, p < 0.001. A significant improvement was observed when the baricitinib group was compared to SOC in procalcitonin, CRP, D-dimer, neutrophil-to-lymphocyte ratio values, and NEWS2. Conclusion. Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy. MDPI 2023-03-10 /pmc/articles/PMC10053916/ /pubmed/36983910 http://dx.doi.org/10.3390/life13030755 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Obradović, Dušanka Popović, Milica Banjac, Maja Bulajić, Jelena Đurović, Vladimir Urošević, Ivana Milovančev, Aleksandra Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study |
title | Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study |
title_full | Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study |
title_fullStr | Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study |
title_full_unstemmed | Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study |
title_short | Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study |
title_sort | outcomes in covid-19 patients with pneumonia treated with high-flow oxygen therapy and baricitinib—retrospective single-center study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053916/ https://www.ncbi.nlm.nih.gov/pubmed/36983910 http://dx.doi.org/10.3390/life13030755 |
work_keys_str_mv | AT obradovicdusanka outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy AT popovicmilica outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy AT banjacmaja outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy AT bulajicjelena outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy AT đurovicvladimir outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy AT urosevicivana outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy AT milovancevaleksandra outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy |